Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Elagolix: Phase III started

Neurocrine said AbbVie began the double-blind, placebo-controlled, international Phase III M12-671 trial to evaluate 2 doses

Read the full 160 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE